Andecaliximab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Andecaliximab
Monoclonal antibody
Type ?
Source Chimeric (mouse/human)
Target gelatinase B
Clinical data
Synonyms GS-5745
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6396H9868N1680O2010S46
Molar mass 143.9 g/mol

Andecaliximab (GS-5745) (INN[1]) is a humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

This drug was developed by Gilead Sciences, Inc.[2]

It is currently at Phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma.

References[edit]